Abstract Von Willebrand factor and platelet membrane glycoprotein lb receptors interact to mediate platelet adhesion and thrombogenesis in stenosed and endothelium-injured arteries. We wished to determine whether blocking glycoprotein Ib receptors with a recombinant von Willebrand factor binding domain (VCL) increases the time required for thrombus formation after injury to the coronary arteries. We also wished to determine whether, after thrombolysis with tissue plasminogen activator (TPA), VCL delays or protects against coronary artery reocclusion. Twenty-seven dogs were treated with either saline, VCL, or aspirin before thrombosis was induced in their coronary arteries by electrical injury. The time from injury to the formation of occlusive thrombi was significantly greater with VCL (70±10 minutes) and aspirin (69±20 minutes) than with saline (18±3 minutes, P<.001 and P<.05). Thrombosis was induced in 30 other dogs that then received thrombolytic treatment in four groups. Our major finding was that coronary artery reocclusion occurred in 72±11 minutes after treatment with TPA (80 ,ug/kg+8 ,gg kg-* min`) and heparin (200 U/kg) (n=7); in 142±24 minutes after TPA, heparin, and VCL (4 mg/kg+2 mg -kg-'. h') (n=7) (compared with TPA and heparin, P<.05); in 74±13 minutes after TPA, heparin, and aspirin (5 mg/kg) (n=8); and in 173±8 minutes after TPA, heparin, VCL, and aspirin (n=8) (compared with TPA and heparin, P<.001). Thus, VCL increases the length of time required for thrombus formation in coronary arteries, and, when given with TPA and heparin, delays coronary artery reocclusion more effectively than aspirin. (Circulation. 1994;89:2822-2828 (Reference 23). We used a canine model to determine the effect of VCL on (1) the formation of intracoronary thrombosis and (2) reocclusion of coronary arteries after thrombolysis with TPA. Our results suggest that VCL delays thrombus formation and reocclusion of coronary arteries.
Studies have revealed that most acute transmural (Q-wave) myocardial infarctions are caused by thrombus formation in atherosclerotic coronary arteries.1-4 An interruption of the protective endothelium covering the vessel wall results in platelet adhesion and aggregation and thrombosis, which blocks the blood supply to the myocardium.5-8 Thrombolytic agents, such as tissue plasminogen activator (TPA) and streptokinase, have been effective in the treatment of thrombosis in patients with acute transmural myocardial infarction (Q-wave infarcts),9-1l but 15% to 20% of patients do not achieve reperfusion. In addition, reocclusion of coronary arteries has limited the efficacy of thrombolytic therapy in some patients. '2"13 In both thrombosis and reocclusion of coronary arteries, platelet adhesion is the initiating event. In platelet adhesion, von Willebrand factor, a multivalent protein, forms a bridge between the subendothelial extracellular matrix and glycoprotein lb on the surface of circulating platelets.14-16 The adhesion of platelets to subendothelium results in activation of platelets and the release of ADP, thromboxane, and serotonin. These in turn activate additional platelets.17-20 Ultimately, a platelet-initiated thrombus forms. Therefore, preventing platelet adhesion may be useful in preventing thrombosis and reocclusion in coronary arteries.2' Several fragments isolated from von Willebrand factor have been shown to bind to the platelet membrane glycoprotein Ib receptor and inhibit the interaction of von Willebrand factor with glycoprotein lb receptors. This inhibition has led to the inhibition of platelet adhesion and aggregation.2223 VCL (Bio-Technology General Inc) is a recombinant fragment of von Willebrand factor, Leu504-Lys728, with a single intrachain disulfide bond that links residues Cys'0 and Cys695 (Reference 23). We used a canine model to determine the effect of VCL on (1) the formation of intracoronary thrombosis and (2) reocclusion of coronary arteries after thrombolysis with TPA. Our results suggest that VCL delays thrombus formation and reocclusion of coronary arteries.
Methods
All procedures used in this study were 
Protocol 2
To further explore the effect of VCL on thrombolysis and reocclusion, additional animals were studied and treated 3 hours after the occlusion of coronary arteries ( Fig 1B) . These animals were assigned to one of four additional groups: TPA and heparin (group 4, n=7); TPA, heparin, and VCL (group 5, n=7); TPA, heparin, and aspirin (group 6, n=8); and TPA, heparin, VCL, and aspirin (group 7, n=8). Heparin was given at 200 U/kg as an intravenous bolus. TPA, VCL, and aspirin were given at the same dose as in protocol 1. The follow-up for thrombolysis and reocclusion was also the same as in protocol 1.
Pharmacokinetic Studies
The pharmacokinetics of VCL were studied in 6 dogs: 3 received VCL at 4 mg/kg as an intravenous bolus; the other 3 received VCL as described for group Hematocrit, Coagulation, and Platelet Aggregation Studies
Hematocrit was determined before and at the end of TPA administration in all dogs in protocol 2. Activated whole-blood clotting time was measured in these dogs before and 5, 60, 120, and 180 minutes after the administration of TPA on an automated blood coagulation timing device (HemoTec 2001370). Hemoglobin and platelet count were measured in 3 dogs before and after the treatments with TPA, heparin, and VCL.
Ex vivo platelet aggregation was analyzed before and 10 minutes after the administration of VCL and aspirin in dogs in protocol 1. Blood samples were collected in plastic tubes containing a 3.8% solution of sodium citrate (9 vol blood to 1 vol sodium citrate). Platelet-rich plasma was obtained by centrifuging blood samples at 200g for 20 minutes, and platelet-poor plasma was obtained by centrifuging the residual blood at 3000g for 10 minutes. The platelet count in plateletrich plasma was adjusted to 300 000/mm3. A four-channel platelet aggregometer (Bio-Data, model PAP-4) was used for the assay. aggregation by inducing von Willebrand factor to bind to the membrane glycoprotein Ib, an action resembling that of ristocetin.2425 Because canine platelets do not aggregate in response to arachidonic acid, epinephrine was added to the platelet suspension at 10 ,umol/L before arachidonic acid. The degree of platelet aggregation was reported as the maximal percentage that light transmission increased in platelet-rich plasma over light transmission in platelet-poor plasma.
Statistical Analyses
All values are expressed as mean+SEM. Fisher's exact test was used to compare the frequency of reperfusion and reocclusion in different groups of animals. A one-way ANOVA with repeated measurements was used to compare the hemodynamic values and activated clotting times obtained at different time periods and the duration of time to reperfusion and reocclusion in different groups of animals. The Student's t test was used to compare the percentage of platelet aggregation and hematocrit values before and after treatment in each group of animals. A value of P<.05 was considered significant.
Results

Intracoronary Thrombus Formation
Insertion of the electrode needle into the coronary artery caused some stenosis in the arteries of all animals, as determined by a reduction of blood flow velocity to approximately 65% of the baseline level. After electrical stimulation, all animals developed total occlusion of the affected coronary arteries. In protocol 1, the elapsed time from electrical stimulation to total occlusion of the coronary arteries was significantly longer in dogs treated with VCL (P<.001) and aspirin (P<.05) than in dogs treated with saline (Fig 2) . In all animals, aortic blood pressures and heart rates changed slightly after the occlusion of coronary arteries. Thrombolysis
In protocol 1, 3 hours after the occlusion of coronary arteries, only TPA was given to the animals. The In protocol 2, dogs were not pretreated before their coronary arteries were occluded, and 3 hours after the occlusion of coronary arteries, they received thrombolytic treatments: TPA and heparin induced thrombolysis in 5 of 7 dogs (71%); TPA, heparin, and VCL induced thrombolysis in 6 of 7 dogs (86%); TPA, heparin, and aspirin induced thrombolysis in 7 of 8 dogs (85%); and TPA, heparin, VCL, and aspirin induced thrombolysis in 8 of 8 dogs (100%). The average thrombolysis time in dogs treated with TPA, heparin, VCL, and aspirin was slightly more than half that in dogs treated only with (Fig 6) .
Pharmacokinetic Studies
A plasma concentration of VCL at 20.6±0.6 ,g/mL was detected at 10 minutes after VCL was injected as an intravenous bolus at 4 mg/kg. Thereafter, the VCL level decreased constantly (Fig 7) . The half-life of VCL was 24 minutes. After the injection and continuous infusion of VCL (4 mg/kg+2 mg . kg-1 . h-'), the level of VCL reached a plateau in 60 minutes at approximately 10 ,ug/mL (Fig 8) . 269 x 1000/mm3 at 3 hours after treatment with TPA, heparin, and VCL (P>.05). Activated clotting time was significantly prolonged immediately after TPA and heparin administration (to a peak of 6 times the baseline value in 10 minutes). It returned to 1.5 times the baseline value 1 hour after treatment and to just above the baseline value 3 hours after treatment. The addition of aspirin, VCL, or aspirin and VCL did not affect activated clotting time.
Ex vivo platelet aggregation induced by ADP was not affected by VCL infusion (Fig 9A) , but it was slightly reduced by aspirin injection (Fig lOA) . The botrocetininduced platelet aggregation was completely inhibited by VCL treatment (Fig 9B) , and arachidonic acidinduced platelet aggregation was completely inhibited by aspirin injection (Fig lOB) . Discussion VCL, a fragment of the binding domain of von Willebrand factor, is an antagonist of the platelet gly- '38 In our study, when VCL was given with TPA or with TPA and heparin, the time from thrombolysis to coronary artery reocclusion was significantly prolonged, and in as many as two thirds of the animals, reocclusion was prevented. VCL was more effective than aspirin given under the same conditions. VCL mainly inhibits platelet adhesion. The success of VCL in preventing reocclusion in two thirds of the animals suggests that a complete or nearly complete dislodgment of aggregated and adhered platelets may have occurred during thrombolysis. The protection from VCL against further platelet adhesion prevented or delayed rethrombosis. Alternatively, the failure of VCL to prevent reocclusion in the other one third of the animals may be due to incomplete dislodgment of thrombi after thrombolysis, followed by further accumulation of platelet aggregates and complete reocclusion. To prevent this chain of events, an additional drug may be needed to inhibit platelet aggregation. Support for this hypothesis comes from our results: reocclusion was prevented in nearly 90% of animals treated with TPA, heparin, VCL, and aspirin. These data suggest that VCL may be useful as adjunctive therapy to TPA in future thrombolytic therapy for coronary artery reocclusion.
Bleeding is a common complication of thrombolytic therapy. In our study, treatment with VCL, TPA, and heparin caused mild to moderate bleeding around the surgical incisions, and the addition of aspirin to VCL, TPA, and heparin resulted in severe bleeding in 2 out of 8 cases. However, hematocrit and hemoglobin levels were not significantly changed. This lack of change may be due to the blood concentration that occurs immediately after bleeding. The decrease of aortic pressure in dogs treated with either TPA, heparin, and VCL or TPA, heparin, VCL, and aspirin may reflect a loss of blood volume. These data indicate that caution will be needed when administering such adjunctive thrombolytic therapy.
Conclusions
Blocking platelet glycoprotein lb receptors with VCL may be effective in diminishing the formation of thrombi in injured coronary arteries. In delaying reocclusion of the coronary arteries after thrombolysis, VCL is comparable or superior to aspirin as an adjunctive treatment with TPA and heparin. Treatment with VCL and aspirin, in addition to TPA and heparin, either markedly delays or prevents reocclusion in this experimental model.
